Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Amivantamab

Amivantamab in ACC

Trisha Wise-Draper (investigator) · Phase 2 · Active, not recruiting · Enrollment 21

NCT05074940

Catalyst Primary completion. 03.02.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
AmivantamabACC (n = 21)not stated in sourceSingle armn/rresponders: 1 patients (of 21), results posted 05.08.2026median progression-free survival: 4.6 months, results posted 05.08.2026